secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001628280-23-006560
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive receives $11.5M payment from Indivior, extends commercial agreement to 2026
--------------------------------------------------------------------------------

- Amendment No. 11 extends Commercial Exploitation Agreement with Indivior to August 16, 2026, with automatic one-year renewals.
- Indivior paid $11.482 million, including $5.482M for 2022 and estimated 2023 price increases.
- Amendment revises transfer pricing and payment terms for supplied product.
- Agreement will not auto-renew after last product patent expires; earlier termination rights remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023006560/0001628280-23-006560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023006560/aqst-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer